Literature DB >> 10675082

Neuroleptic malignant syndrome after venlafaxine.

S R Nimmagadda, D H Ryan, S L Atkin.   

Abstract

A patient developed neuroleptic malignant syndrome after a single dose of venlafaxine with trifluoperazine treatment. A dopamine-inhibition effect induced by one dose of venlafaxine may have augmented dopamine-receptor inhibition by trifluoperazine.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10675082     DOI： 10.1016/S0140-6736(99)03514-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  3 in total

1.  Drug-induced movement disorder and confusion associated with duloxetine.

Authors:  Sarah Hasan Siddiqui; Nadeem Ahmed Memon; Ravi Shanker
Journal:  BMJ Case Rep       Date:  2018-03-28

2.  Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report.

Authors:  Chee Keong Chang; Alvin Oliver Payus; Malehah Mohd Noh; Meryl Grace Lansing; Doreen Sumpat; Sooth Jiun Andrea Lu; Boon Teong Yew
Journal:  J Med Case Rep       Date:  2022-10-06

3.  Olanzapine-associated neuroleptic malignant syndrome: Is there an overlap with the serotonin syndrome?

Authors:  Vassilis P Kontaxakis; Beata J Havaki-Kontaxaki; Nikolaos G Christodoulou; Konstantinos G Paplos; George N Christodoulou
Journal:  Ann Gen Hosp Psychiatry       Date:  2003-10-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.